Abstract 17199: Cost-Effectiveness of Fondaparinux versus Enoxaparin in Non-st-Elevation Acute Coronary Syndrome in Canada. Oasis-5

Purpose: To estimate the lifetime cost-effectiveness of fondaparinux compared to enoxaparin for non-ST-elevation acute coronary syndrome (NSTE-ACS) patients in a Canadian hospital setting. Methods: An event-based decision analytic model was constructed using clinical and resource use data from OASIS-5, a randomised trial of 20,078 patients from 41 countries. A public payer perspective in the hospital setting was adopted. The probabilities of death, non-fatal myocardial infarction (MI), non-fatal stroke, and major and minor bleeds over a period of 180 days, for both treatment strategies, were estimated using a set of risk equations derived from OASIS-5 data. Resource use data from the trial were valued using Canadian costs. A cost regression model was developed to estimate the mean cost of managing the clinical events over the 180 day period. Annual costs of long-term care for ACS patients were added after 180 days until death. Long-term survival was incorporated using Canadian life tables with further adj...